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2Abstract
Most of diabetic cardiovascular complications are attributed to endothelial dysfunction and 
impaired angiogenesis. Endoplasmic Reticulum (ER) and oxidative stresses were shown to 
play a pivotal role in the development of endothelial dysfunction in diabetes. 
Hemeoxygenase-1 (HO-1) was shown to protect against oxidative stress in diabetes; 
however, its role in alleviating ER stress-induced endothelial dysfunction remains not fully 
elucidated. We aim here to test the protective role of HO-1 against high glucose-mediated ER 
stress and endothelial dysfunction and understand the underlying mechanisms with special 
emphasis on oxidative stress, inflammation and cell death.
Human Umbilical Vein Endothelial Cells (HUVECs) were grown in either physiological or 
intermittent high concentrations of glucose for 5 days in the presence or absence of Cobalt 
(III) Protoporphyrin IX chloride (CoPP, HO-1 inducer) or 4-Phenyl Butyric Acid (PBA, ER 
stress inhibitor). Using an integrated cellular and molecular approach, we then assessed ER 
stress and inflammatory responses, in addition to apoptosis and angiogenic capacity in these 
cells.
Our results show that HO-1 induction prevented high glucose-mediated increase of mRNA 
and protein expression of key ER stress markers. Cells incubated with high glucose exhibited 
high levels of oxidative stress, activation of major inflammatory and apoptotic responses 
[nuclear factor (NF)-κB and c-Jun N-terminal kinase (JNK)] and increased rate of apoptosis; 
however, cells pre-treated with CoPP or PBA were fully protected. In addition, high glucose 
enhanced caspases 3 and 7 cleavage and activity and augmented cleaved poly ADP ribose 
polymerase (PARP) expression whereas HO-1 induction prevented these effects. Finally, 
HO-1 induction and ER stress inhibition prevented high glucose-induced reduction in NO 
release and impaired the angiogenic capacity of HUVECs, and enhanced vascular endothelial 
growth factor (VEGF)-A expression. 
3Altogether, we show here the critical role of ER stress-mediated cell death in diabetes-
induced endothelial dysfunction and impaired angiogenesis and underscore the role of HO-1 
induction as a key therapeutic modulator for ER stress response in ischemic disorders and 
diabetes. Our results also highlight the complex interplay between ER stress response and 
oxidative stress.
Key words: Endothelial dysfunction, ER stress, oxidative stress, Heme oxygenase-1
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Phenyl Butyric Acid (PBA, PubChem CID:4775), Sn Protoporphyrin IX dichloride (SnPP, 
PubChem CID: 73755113).
41. Introduction
Endothelial dysfunction generally refers to structural and functional impairment of 
endothelium including damage at the cellular level. It plays a key role in the pathogenesis of 
various cardiovascular diseases, such as atherosclerosis, diabetic complications, and 
hypertension. Heme oxygenase (HO) is one of the cyto-protective proteins that could confer a 
beneficial effect in vasculature. HO originally functions as a rate-limiting enzyme in heme 
degradation, yielding carbon monoxide (CO), iron, and biliverdin as the end products. HO-1 
and HO-2 are isoforms of HO in mammals [1]. The HO-2 isoform is constitutively expressed; 
however, HO-1 is an inducible one. HO-1 expression can be induced by many structurally 
different molecules and by cellular stress such as heat shock [2]. In particular, the role of 
hemeoxygenase-1 (HO-1) as a protective enzyme is well known. Its anti-oxidant, anti-
apoptotic, and anti-inflammatory effects have been extensively studied [2, 3]. The cyto-
protective effect of HO-1 may have several distinct underlying mechanisms, including the 
degradation of heme to the anti-oxidant bilirubin, the co-ordinate induction of ferritin, which 
chelates the pro-oxidant free iron, and release of carbon monoxide (CO), which exerts 
significant anti-inflammatory and anti-apoptotic effects [4].
HO-1 can be induced by numerous oxidizing agents and stimuli, including ultraviolet 
radiation, heavy metals, cytokines and heme/hemoglobin [2, 5]. It is now well established
that HO-1 can provide anti-oxidation and cyto-protection in in vitro and in vivo systems. 
There is convincing evidence indicating that HO-1 can protect the vasculature against 
resinamodeling and endothelial dysfunction [6]. Furthermore, HO-1 is currently regarded as a 
novel therapeutic target in the treatment of vascular disease, and several strategies have been
employed to target this enzyme in the vasculature. A variety of pharmacological agents of 
different chemical structures have been shown to protect against the development of vascular 
disease in numerous studies in vivo [7, 8]. Moreover, Yang et al. [9] demonstrated the anti-
5oxidant protective role of HO-1 in vitro by reducing endogenous reactive oxygen species 
(ROS) production in HUVECs when grown in serum from rats exposed to cigarette smoke
[9]. Concerning the anti-inflammatory role of HO-1, Chang et al. [10] successfully 
highlighted this role in HUVECs treated with iodine-based contrast media that was used as an 
inflammatory model in this study. They showed that HO-1 induction reduced ICAM-1 and 
adhesion molecules receptor expression [10]. About the anti-apoptotic effects of HO-1,
Abraham et al. [11] have previously reported that the overexpression of HO-1 in human 
dermal microvessel endothelial cells prevented high glucose-mediated slowdown of cell 
cycle progression and increase in apoptosis [11]. Utilizing Zucker diabetic fat rats (ZDF), it 
has also been reported that the induction HO-1expression at the early stages of diabetes using 
cobalt protoporphyrin (CoPP) and stannous chloride (SnCl2) imporved blood pressure and 
reduced endothelial cell sloughing and strongly upregulated anti-apoptotic signals including 
Bcl-xl and Bcl-2 [12].
Despite the cyto-protective effects of HO-1 that have been well-documented in literature, the 
role it plays with regards to ER stress response which has been shown in recent years to be 
involved in the pathophysiology of insulin resistance/diabetes [13] and in the development of 
endothelial dysfunction [14] is not fully elucidated. The ER is the site of protein secreted 
synthesis and folding. Upon disruption in protein folding or modification within the ER, a 
state of stress ensues, resulting in the unfolded protein response (UPR) with the aim to return 
the ER to its physiological state and enhance cell survival [15-17]. The UPR functions via 
signalling through three stress-sensing proteins found on the ER membrane: PKR-like 
eukaryotic initiation factor 2α kinase (PERK), inositol-requiring kinase-1α (IRE-1α), and 
activating transcription factor (ATF)-6. The ER luminal domains of PERK, IRE-1α, and 
ATF-6 interact with the ER chaperone Binding immunoglobulin protein (BiP). BiP is 
responsible for maintaining the effectors of UPR response under inactive form. Under stress 
6conditions, accumulation of misfolded or unfolded proteins within ER, BiP dissociates from 
these sensor proteins, which thereby become active. However, prolonged UPR activation 
leads to apoptosis, oxidative stress, and inflammation and is referred to as the “ER stress 
response”. Diabetes results in metabolic conditions that increase the demand on the ER for 
protein and lipid synthesis [15]. Several studies including ours have shown that insulin 
resistant states such as obesity promote ER stress response in various tissues such as liver, 
adipose tissue, and the heart [13, 18, 19]. 
Activated PERK phosphorylates, and thus activates, eIF (eukaryotic initiation factor)-2α, 
thereby reducing general protein translation. However, the translation of ATF-4 is selectively 
permitted. ATF-4 is required for the expression of pro-apoptotic CCAAT/enhancer-binding 
protein homologous protein (CHOP) transcription factor that plays a key role to ER stress-
mediated cell dysfunction. CHOP upregulates expression of pro-apoptotic proteins such as 
Bim, and downregulates expression of anti-apoptotic molecule Bcl-2 [16, 17]. ER stress 
causes insulin resistance and participates in the low-grade inflammation observed in insulin 
resistant states [13, 20] by mediating cell death and the activation of inflammatory 
pathways such as nuclear factor-κB (NF-κB) and c-Jun N-terminal kinase (JNK) [15]. An 
association between ER stress and endothelial dysfunction was reported in experimental 
models of diabetes [14, 21]; however, the underpinning mechanisms are unclear especially 
regarding the role of ER-stress mediated inflammation and cell death.
The aim of this study was to show in the context of a high glucose environment, how HO-1 
induction would affect ER stress-induced endothelial dysfunction and angiogenic capacity in 
endothelial cells. As such, we hypothesized that HO-1 would reduce ER stress response 
activity and hence improve ER stress-mediated inflammation, oxidative stress and apoptosis, 
which are major molecular contributors to endothelial dysfunction, the initial step in the 
development of atherosclerosis. 
7By using human vascular endothelial cells as a model, we provide evidence that HO-1 
induction exerts a protective role against ER stress-mediated endothelial dysfunction and 
impaired angiogenic capacity caused by high glucose treatment. The effects of HO-1 
induction involve several protective mechanisms including the alleviation of oxidative stress
in addition to inflammatory and apoptotic responses induced by ER stress activation. We 
show here, the critical role of ER stress-mediated cell death in diabetes-induced endothelial 
dysfunction and impaired angiogenic capacity. These results underscore the role of HO-1 
induction as a key modulator for ER stress response in metabolic disorders and diabetes.
82. Materials & Methods
2.1. Cell culture and treatments
Human Umbilical Vein Endothelial cells (HUVECs) were obtained from Life Technologies 
(Paisley, UK) and were routinely cultivated in M200 medium (Gibco, Paisley, UK) 
supplemented with low serum growth supplement (LSGS; Gibco, Paisley, UK) containing 
2% of foetal bovine serum and were maintained at 37°C in a humidified atmosphere with 5% 
CO2. Cells were used for experiments up to passage 6.
To assess the effects of high glucose on endothelial cells, HUVECs were incubated either 
with culture medium containing a physiological concentration of glucose (5 mM) or cultured 
in high glucose (33 mM) for 5 days with intermittent recovery periods of 8 hours with 
medium containing 5 mM of glucose [16 hours in high glucose (33 mM) followed by 8 hours 
in normal glucose (5 mM) for 5 consecutive days]. M200 culture medium was supplemented 
with D-glucose (SigmaAldrich, Gillingham, UK) to the desired concentration. To factor out 
the osmotic stress effect which high glucose treatments may have cells, mannitol 
(SigmaAldrich, Gillingham, UK) was used as an osmotic stress control where a control 
groups of HUVECs were treated in similar fashion to the high glucose group, with medium 
supplemented with mannitol (33 mM) with 8 hours recovery periods for 5 days.
To induce HO-1 induction, Cobalt (III) Protoporphyrin IX chloride (CoPP, 10 µM;
SigmaAldrich, Gillingham, UK), a potent HO-1 inducer, was added to HUVECs on the 5th
day of glucose treatment 1 hour before the last high glucose treatment and kept for an 
additional 12 hours before the harvest. A dose- and time-course were established to 
determine the best CoPP concentration and incubation time to induce HO-1’s expression in 
HUVECs. 
9To ascertain that effects observed are due to an increase in HO-1’s activity, in some 
experiments cells were treated with Sn-protoporphyrin IX (SnPP) (20 µM; SigmaAldrich, 
Gillingham, UK) which was added to cells 1 hour before CoPP before the last high glucose 
treatment and then kept for an additional 12 hours before the harvest. SnPP, a 
metalloporphyrin formed by a chelate of tin with the porphyrin ring, is a potent inhibitor of 
both HO-1 and HO-2 activities. It induces HO-1 synthesis, but potently inhibits the enzyme’s 
activity by acting as a competitive substrate for heme at the catalytic site [22]. 
To assess the involvement of ER stress response, some cells were treated with the chemical 
chaperone, 4-Phenyl Butyric Acid (PBA, 10 mM; SigmaAldrich, Gillingham, UK) to inhibit 
ER stress [20]. PBA was added to cells 1 hour before the last high glucose treatment and then 
kept for an additional 12 hours before the harvest.  
As a positive control for oxidative stress, some cells were treated with H2O2 (100 μM; 
SigmaAldrich, Gillingham, UK) for 30 minutes to induce ROS release.
As a positive control for cell death, some cells were stimulated with Staurosporine (1 µM; 
SigmaAldrich, Gillingham, UK) for 12 hours to induce apoptosis.
A positive control for induction of IL-6 synthesis and release, some cells were incubated with 
lipopolysaccharide (LPS; E. coli serotype O111:B4) 1 µg/ml (Cell Signaling by NEB, 
Hitchin, UK) at 1 µg/ml for 8 hours prior to assessing IL-6 release in culture medium by 
ELISA.  
2.2. Total RNA isolation and gene expression analysis
After incubation of HUVECs with high glucose in the presence or absence of modulators of
ER stress response or HO-1 inducer, total RNA was isolated using Qiagen RNeasy mini kit 
(Qiagen, Manchester, UK) following the manufacturer’s protocol. 
10
Before cDNA synthesis, total RNA was treated with DNAase I to digest any excess genomic 
DNA. First strand cDNA was synthesized from 1 µg of total RNA employing the RevertAid 
First Strand cDNA Synthesis Kit (ThermoScientific, Loughborough, UK) and an oligo(dT)12-
18 primer as reverse primer. Then, target genes were amplified by real-time PCR using GoTaq 
qPCR Master Mix (Promega, Southampton, UK) in Applied Biosystems 7500 Real-Time 
PCR System (ThermoScientific, Loughborough, UK).
Total cDNA samples with known quantities in ng (100 ng/µl, 10 ng/µl, 1.0 ng/µl, 0.1 ng/µl 
and 0.01 ng/µl) were prepared from HUVECs stimulated with thapsigargin. These samples 
were used to generate standard curves for genes of interest. These standard curves were then 
used to determine the relative mRNA expression levels in HUVECs. 
Primer pairs for target genes were obtained from Primer bank. Human primer sequences used 
in the study are as follows: 
GAPDH_F 5’- CCAGCCGAGCCACATCGCTC -3’
GAPDH_R 5’- ATGAGCCCCAGCCTTCTCCAT -3’
β-actin _F 5’- CATCACGCCGTCCTATGTCG -3’
β-actin _R 5’- CGTCAAAGACCGTGTTCTCG -3’
ATF-4_F 5’- GAACGGCTCAAGCAGGAAATC -3’
AFT-4_R 5’- TTCACCATTCGGTCAATCAGAG -3’
BiP_F 5’- GCTGACGATGAAGTTGATGTGG -3’
BiP_R 5’- CATCCGTCCTTGATCCTTCTCTA -3’
CHOP_F 5’- CCCTTCACCTTCTTACAACCTC -3’
CHOP_R 5’- TGCCCAGCTCTAAACTAAAGGA -3’
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IL-6_F 5’- TGATGGCGAAGCGAGTGAAG -3’
IL-6_R 5’- ACTCATCCATACACAGGACCC -3’
VEGF-A_F 5’- GGTGGGCCAAAGGATGAAGAG -3’
VEGF-A_R 5’- CCACAAGCCAAACGACTTCC -3’
2.3. Western blotting
After cell treatments, whole-cell lysates were prepared by extraction in radioimmuno-
precipitation assay (RIPA) (10 mM Tris-HCl, pH 7.4; 150 mM NaCl; 0.1% SDS; 1% Triton-
X100; 1% Sodium deoxycholate; 1 mM NaF; 5 mM EDTA; 1 mM sodium orthovanadate; 
cocktail of protease inhibitors) as described previously [18, 23]. Proteins of equal amounts 
(10-20 µg) were then separated on 8-12% SDS-PAGE gels (ThermoScientific, 
Loughborough, UK). Immunoblots were performed using antibodies against: ATF-4, p-eIF-α 
(Ser51), caspase 3, cleaved caspase 3,  caspase 7, cleaved caspase 7, PARP, cleaved PARP, 
p-iKK α/β (Ser176/180), iKK, p-c-JUN (Ser63), p-Akt (Ser473), Akt, p-eNOS (Ser1177), 
eNOS (Cell Signaling by NEB, Hitchin, UK), p-p47phox (Ser345), p47phox, VEGF-A
(SigmaAldrich, Gillingham, UK), BiP, HO-1, β-actin (Santa Cruz by Insight Biotechnology, 
Wembley, UK). Proteins were then visualized using fluorescent secondary antibodies and 
Odyssey CLx infrared imaging system (Li-COR Biosciences, Cambridge, UK) according to 
manufacturer’s guidelines. Signal was then quantified using Image Studio software from Li-
COR Biosciences (Cambridge, UK). 
2.4. Assessment of cell death
Cell apoptosis was assessed by flow cytometry analysis using an Annexin V Apoptosis 
Detection Kit APC (eBioscience, Altrincham, UK) as described previously [24].  Briefly, 
after treatments, cells were collected by trypsinization and were re-suspended in incubation 
buffer containing Annexin V-PE and propidium iodide (1µg/ml), incubated in the dark at 4°C 
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for 10 minutes, and then fixed in 1% formaldehyde.  Cells were then re-suspended in 
incubation buffer and analysed in a BD FACSCanto™ II (BD Bioscience, Oxford, UK). Cell 
apoptosis was expressed as the percentage of apoptotic cells expressed as the total number of 
cells. Some cells were treated with Staurosporine (1 µM; SigmaAldrich, Gillingham, UK) for 
3 hours and were used as a positive control for apoptosis while untreated cells were used a 
negative control.
2.5. Caspases 3/7 activity
HUVECs were cultured in physiological concentration of glucose (5 mM) or in intermittent 
high glucose (5/33 mM) for 5 days in the absence or presence of PBA or CoPP. As positive 
control, some cells were treated with Staurosporine (1 mM) for 3 hours while untreated cells 
were used a negative control. Then, caspases 3/7 activity was measured using Caspase-Glo® 
3/7 Assay (Promega, Southampton, UK) according to the manufacturer’s guidelines. 
Caspase-Glo® 3/7 reagent contains a luminogenic substrate (Aminoluciferin) attached to 
tetra-peptide sequence Z-DEVD, which is specific for protease cleavage by caspases 3 and 7. 
Caspases 3 and 7 cleave Z-DEVD releasing Aminoluciferin which is a luminescent substrate 
for the luciferase reaction. The light output from the luciferase reaction is directly 
proportional to the activity of the enzymes. The activity of caspases 3 and 7 was determined 
using a LUMIstar Omega luminometer (BMG LABTECH, Aylesbury, UK).
2.6. ELISA analysis of IL-6 production
HUVECs were incubated in physiological concentration of glucose (5 mM) or in intermittent 
high glucose (5/33 mM) for 5 days in the presence or absence of CoPP  (10 µM) and/or SnPP 
(20 µM). A positive control was generated by treating some cells with lipopolysaccharide 
(LPS; Cell Signaling by NEB, Hitchin, UK) at 1 µg/mL for 30 minutes.  Supernatants were 
collected and centrifuged at 10,000 x g for 10 minutes to rem ove dead cells and any debris 
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and then assayed for IL-6 using an ELISA kit (ThermoScientific, Loughborough, UK) 
according to the manufacturer’s instructions.
2.7. Nitrite and nitrate measurement by Griess assay
The production of NO was also quantified by measuring the released NO metabolites (nitrite 
and nitrates) with Griess reagent (Life Technologies, Loughborough, UK). The Griess assay 
was used to measure the concentration of nitrite/nitrate that are stable by-products of NO 
degradation as an indirect way of estimating production of NO in HUVECs. Culture medium 
samples were collected from control and high glucose-treated cells in the presence or absence 
of PBA or CoPP. Culture medium samples were then centrifuged to remove dead cells and 
cell debris. The medium was subsequently processed to determine nitrate and nitrite 
concentrations according to the manufacturer’s protocol [25].
2.8. ROS measurement by dihydroethidine (DHE) staining
HUVECs were cultured in physiological concentration of glucose (5 mM) or in intermittent
high glucose (5/33 mM) for 5 days in the absence or presence of PBA or CoPP. As a positive 
control, H2O2 (100 μM) was added to some cells for 30 minutes to induce ROS release.
Osmotic stress was controlled by growing cells in medium where glucose was replaced by 
mannitol (33 mM). Following this, cells were washed three times with phosphate buffer salt 
(PBS) solution, and then incubated with the oxidative fluorescent dye DHE (10 μM; 
SigmaAldrich, Gillingham, UK) for 30 minutes. Cells were then harvested, washed three 
times with PBS and then fluorescence at 620 nm was determined and the number of DHE-
positive cells was calculated using a FACSCanto™ II flow cytometry (BD Bioscience, 
Oxford, UK). Negative and positive cells were then plotted using the positive control and 
DHE negative cells (untreated cells). Cells shifting to the right channel were considered as 
positive for DHE [25, 26].
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2.9. In vitro tube-like structure formation assay on Matrigel® matrix
HUVECs were incubated in physiological concentration of glucose (5 mM) or in intermittent 
high glucose (33 mM) for 5 days in the presence or absence of PBA or CoPP. Then, they 
were seeded (105 cells per well) on 24-well culture plates coated with a basement membrane 
preparation extracted from Engelbreth-Holm-Swarm murine sarcoma (Matrigel®; BD 
Bioscience, Oxford, UK) [27]. Briefly, 250 µL of Matrigel® substrate diluted with serum-
free medium (1∶1 dilution) was added into each well of 24-well plates and allowed to solidify 
for 1 hour at 37°C. Then, cells were incubated with M200 medium supplemented with LSGS
and allowed to adhere for 1 hour. Untreated cells cultured in M200 medium without LSGS 
were used as the negative control, while those cultured in M200 medium supplemented with 
the LSGS that has 2% FBS + 3 ng/mL β-FGF were used as positive control. HUVECs were 
incubated for further 24 hours and tube-like structures formation was examined using an 
inverted phase contrast microscope. Then, using ImageJ software, the length of the tubes 
formed was counted in 5 different blind fields, averaged then compared across the different 
samples.
2.10 Assessment of HO-1 activity (Bilirubin assay)
Bilirubin colorimetric assay kit (Cell Biolabs Inc., San Diego, CA, USA) was used to 
measure the total and direct bilirubin levels in HUVECs’ lysates following the 
manufacturer’s protocol. Briefly, HUVECs were cultured in normal glucose (5 mM) or 
exposed intermittently to high glucose (5/33 mM) for 5 days in the presence or absence of 
CoPP (10 µM) or SnPP (20 µM). Then, cells were lysed with RIPA lysis buffer and 
centrifuged at 10,000 x g for 10 minutes at 4°C. Bilirubin standards were prepared in 1:2 
serial dilutions. Samples and standards were then loaded in duplicates in a 96-well micro-
plate. Accelerant (proprietary reagent) to each well. Diazo reagent was then loaded to 
samples and standards. Reagent A (Sodium hydroxide) was then added to all wells and the
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plate left for incubation for 1 hour at room temperature protected from light. After incubation 
is over, assay reagent B was added and absorbance at 540 nm was measured. The net OD for 
each sample was calculated by subtracting OD from negative control wells from each sample 
well, which was then plotted against standard curve to determine bilirubin levels (mg/dL). 
2.11. Cell viability assay
This viability assay is based on the capacibolity of metabolically active alive cells to covert 
the yellow tetrazolium salt 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT) to purple formazan crystals. This allows a quantitative evaluation of viable cells. 
HUVECs were seeded into 96-well plates at the density of 20,000 cells per mL and then 
grown for 24 hours. Following this, cells were incubated with varying concentrations of 
CoPP (10, 25, 50, 75 and 100 µM) for either 12 or 24 hours. After incubation, we added 
MTT (SigmaAldrich, Gillingham, UK) at final concentration of 0.5 mg/mL to each one of the 
well and incubated cells for further 4 hours at 37°C. Then, culture medium was removed and 
100 μL Dimethyl sulfoxide (SigmaAldrich, Gillingham, UK) were added to each well to 
solubilise the formazan crystals and incubated for further 30 minutes at 37 °C. Absorbance 
was then measured at 570 nm using a multi-plate reader (Molecular Devices, Wokingham, 
UK). The intensity of colour in control wells was used to indicate 100% of viability.
2.12. Data analysis
Results are expressed as mean ± SEM, and n represents the number of mice or biological 
replicates. Statistical analyses were performed using ANOVA (2-way or 1-way, as 
appropriate) followed by Tukey’s or Bonferroni is multiple comparison post-hoc tests. P < 
0.05 was considered to be statistically significant.
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3. Results
3.1. Validation of the conditions of induction of HO-1 by CoPP in HUVECs
To validate the optimal conditions for use of CoPP to induce HO-1 in HUVECs and to ensure 
that the increase in protein levels is indeed reflecting an increase in activity, we conducted a 
series of experiments. We first constructed a dose- and time-course response to varying 
concentrations of CoPP to determine the optimal concentration and time for the induction of 
HO-1 in HUVECs without causing any non-specific toxicity to the cells. Once determined, 
we evaluated the activity of HO-1 in response to CoPP treatment.
As shown in Figure 1A, the incubation of cells with CoPP at the concentrations of 10, 25, 50, 
75 and 100 µM all caused an increase in protein expression of HO-1 after 12 and 24 hours; 
however, the increase was higher at 12 hours. Furthermore, as shown in Figure 1B, the 
incubation of HUVECs with these different concentrations CoPP for 12 and 24 hours caused 
a significant decrease in cell viability at 24 hours in all concentrations; however, at 12 hours, 
none of these concentrations showed a significant decrease in cell viability.
Altogether, we decided for this project to induce HO-1 expression by treating cells with 
CoPP at the concentration of 10 µM for 12 hours. 
To ascertain that HO-1 expression reflects an increase in its activity, we have assessed the 
enzyme’s activity by measuring the release of heme degradation by-product bilirubin in cells 
treated exposed or not to high glucose in the presence or absence of CoPP, a HO-1 inducer, 
and/or SnPP, a HO inhibitor. As shown in Figure 1C, high glucose did not affect bilirubin 
levels while the induction of HO-1 by CoPP (10 µM, 12 hours) caused an increase of its 
release indicating an increase in HO-1 activity in HUVECs. The pre-treatment of cells with 
SnPP partially, but significantly, prevented the increase in bilirubin caused by CoPP. These 
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data indicate that in our hands the induction of HO-1 by CoPP reflects an increase of the 
enzymes activity. 
3.2. HO-1 induction prevents the induction of ER stress response in HUVECs caused by 
high glucose treatment.
As expected, intermittent high glucose (33 mM) treatment of HUVECs for 5 days induced an 
activation of ER stress response. As shown in Figures (2A, 2B and 2C), high glucose caused 
an increase in mRNA expression of BiP, CHOP and ATF-4 to levels comparable to positive 
control thapsigargin. The pre-treatment of cells with PBA to inhibit ER stress prevented the 
increase in mRNA expression of these key ER stress markers (Figures 2A, 2B and 2C). At 
the protein level, similarly to thapsigargin treatment, the incubation of HUVECs with 
intermittent high glucose enhanced the phosphorylation of e-IF2-α and increased protein 
expression of both BiP (Figure 2D and 2E) and ATF-4 (Figure 2F). Although mannitol
caused a moderate increase in the phosphorylation of e-IF2-α, it did not affect the activation 
of other key ER stress response markers excluding thus any contribution of osmotic stress in 
high glucose-mediated ER stress response. HO-1 induction by CoPP prevented the activation 
of ER stress response in HUVECs as evidenced by the normalisation of e-IF2-α 
phosphorylation and reduction in BiP and ATF-4 protein expression (Figures 2D,  2E and 
2F) indicating a protective role for HO-1 against high glucose-induced ER stress in 
HUVECs.
3.3. HO-1 induction prevents oxidative stress caused by high glucose treatment in 
HUVECs.
The incubation of HUVECs with intermittent high glucose treatment for 5 days caused a 
significant increase in ROS production compared to negative control (Figure 3A). HO-1 
induction by CoPP significantly reduced ROS production to control levels (Figure 3A)
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indicating the protective role that HO-1 has against high glucose-induced oxidative stress. 
Mannitol failed to show any increase in ROS production indicating that these effects shown 
with high glucose treatment are due to metabolic stress and not osmotic stress. PBA treatment 
also significantly reduced ROS production caused by high glucose although not to the same 
extent as CoPP (Figure 3A). These data indicate a considerable degree of ER stress 
involvement in high glucose-mediated increase in ROS production.
NADPH oxidase system is an important source of ROS production in the vasculature 
particularly in endothelial cells [28]. As shown in Figure 3B, when HUVECs were subjected 
to high glucose (33 mM for 5 days with intermittent recovery periods), there was a significant 
increase in the phosphorylation of p47phox regulatory subunit when compared to control 
condition; whereas, co-treatment of cells with CoPP has resulted in a significant reversal of 
such effect. The phosphorylation of regulatory subunit p47phox is believed to be a prerequisite 
for the activation of NADPH oxidase complex [29]. The induction of ER stress response by 
thapsigargin also enhanced the phosphorylation of p47phox and this effect was prevented by 
pre-incubation of cells with PBA, again indicating the involvement of ER stress in this 
process. 
3.4. HO-1 induction prevents ER stress-mediated activation of pro-inflammatory 
signalling pathways caused by high glucose. 
Intermittent treatment of HUVECs with high glucose for 5 days significantly increased 
phosphorylation of inflammatory markers iKK α/β (Figure 4A) and c-JUN (Figure 4B)
compared to control. This effect was also noticeable with thapsigargin treatment and reversed 
by PBA indicating involvement of ER stress in this process. When adding PBA to the cells 
incubated with high glucose, similarly to thapsigargin this has prevented the increase in 
phosphorylation of both iKK α/β and c-JUN (Figure 4A and 4B) indicating that high 
glucose-induced inflammatory response is related to ER stress response induction. Moreover, 
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HO-1 induction by CoPP significantly prevented the increase in phosphorylation of both iKK 
α/β and c-JUN (Figure 4A and 4B) indicating a cross-talk between ROS and ER stress 
response in this process. To further emphasize the involvement of oxidative stress in 
inflammatory response, we were able to observe significant increase in the phosphorylation 
of both inflammatory markers iKK α/β and c-JUN (Figure 4A and 4B) when HUVECs were 
treated with H2O2 (100 µM) for 30 minutes. HO-1 induction prevented the effects of H2O2 on 
phosphorylation of iKK α/β and c-JUN. To exclude the involvement of osmotic stress in this 
inflammatory response, cells were treated with mannitol which did affect the neither the 
expression nor the activation of inflammatory molecules investigated (Figure 4A and 4B). 
In order to ascertain the protective role HO-1 has against high glucose-induced inflammatory 
response in HUVECs, we assessed the production of a key pro-inflammatory cytokine IL-6.
As shown above in Figure 4C, similarly to thapsigargin, IL-6 mRNA levels have 
significantly increased after treatment of cells with intermittent high glucose compared to 
controls. This increase was significantly reversed back to control levels with PBA treatment 
indicating ER stress involvement in this process (Figure 4C). HO-1 induction by CoPP 
reversed the increase in IL-6 mRNA expression both in high glucose and thapsigargin-treated 
HUVECs to bring them back to control levels (Figure 4C). This suggests that the antioxidant 
activity of HO-1 plays a protective role against high glucose-induced inflammation, at least 
partly, through the alleviation of ER stress response. Furthermore, ELISA analysis of IL-6 
protein release in culture medium collected from HUVECs showed a significant elevation in 
IL-6 levels in high glucose culture medium compared to control (Figure 4D). However, 
culture medium harvested from HUVECs treated with high glucose in the presence of CoPP 
showed similar levels of IL-6 expression to negative control clearly indicating a protective 
effect of HO-1 induction against high glucose-mediated inflammation. When SnPP (20 µM), 
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a heme analogue inhibitor of HO, was added 1 hour before CoPP treatment, this has negated 
CoPP effects on high glucose-mediated increase of IL-6 release (Figure 4D).
3.5. HO-1 induction prevents ER stress-mediated apoptosis caused by high glucose 
treatment in HUVECs: Critical role for caspases 3 and 7.
Analysis of apoptosis by flow cytometry showed that amongst HUVECs cultured in 
intermittent high glucose conditions, the percentage of apoptotic cells significantly increased 
to 45% compared to 7% in HUVECs cultured in medium with physiological glucose 
concentration (Figure 5).  However, the percentage of apoptotic cells amongst HUVECs
cultured in intermittent high glucose media was significantly reduced to 15% after HO-1 
induction with CoPP treatment (Figure 5). To further emphasize the anti-apoptotic effect of 
HO-1 induction, SnPP, a HO inhibitor (20 µM), was added 1 hour prior to adding CoPP to 
HUVECs incubated with high glucose. SnPP reversed the protective effects of HO-1 with a 
significant increase in percentage of apoptotic cells to 40% (Figure 5), thus providing further 
evidence on the protective effect of HO-1 against apoptosis in high glucose milieu and 
indicating the key role of ER stress in this process.
To further understand the mechanisms underlying the protective role of HO-1 against high 
glucose-induced apoptosis, we assessed the enzymatic activity of caspases 3/7. As shown in 
Figure 6A, HUVECs cultured in intermittent high glucose (33 mM) conditions showed a 
significant increase in caspases 3/7 activity compared to negative control. This effect was 
negated by CoPP treatment bringing caspases 3/7 activity levels to those of the negative 
control.
Furthermore, we determined by western blot analysis the expression of active (cleaved) 
caspases 3/7 and PARP (a caspase-3 substrate). As shown in Figure 6B, HUVECs incubated 
with high glucose medium (33 mM) exhibited cleavage of caspases 3/7 and PARP indicating 
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the activation of these pro-apoptotic sub-pathways. Similar observations were also noticeable 
with thapsigargin treatment. When adding PBA to cells incubated with high glucose, has 
prevented the cleavage of caspases 3/7 and PARP indicating that high glucose-induced 
apoptotic response involves ER stress response induction (Figure 6B). 
Furthermore, we analysed the cleavage of these three pro-apoptotic effectors (PARP and 
caspases 3/7) following the treatment of HUVECs with H2O2 (100 µM) for 30 minute. H2O2 
caused the cleavage of PARP and caspases 3/7 and this effect was abolished by HO-1 
induction with CoPP treatment. Cells incubated with high glucose and where HO-1 was 
induced by CoPP showed no cleavage of these proteins indicating the protective role HO-1 
plays against oxidative stress-mediated apoptosis (Figure 6B). When cells were treated with 
mannitol, no cleavage of caspases 3/7 or PARP was observed which excludes the 
involvement of osmotic stress in this apoptotic response.
Altogether, our data show that HO-1 induction was able to prevent apoptosis triggered by 
oxidative stress and ER stress response following exposure of endothelial cells to high
glucose. These effects were related to the inhibition of NF-κB and JNK pro-apoptotic and 
inflammatory pathways, alleviation of ER stress response particularly the reduction of CHOP 
expression and to preventing the cleavage of caspases 3/7 and PARP, which play a key 
central role in the final steps of different apoptosis cascades.
3.6. Alleviation of high glucose-induced ER stress by HO-1 induction improves 
endothelial function and angiogenic capacity in HUVECs.
As shown in Figure 7A, high glucose treatment decreased NO production in HUVECs while 
the induction of HO-1 prevented this effect increasing thus NO bioavailability considering 
the concomitant decrease in ROS observed previously (Figure 3). Furthermore, western blot
analysis of key components of NO pathway, showed that HO-1 induction by CoPP strongly 
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enhanced the phosphorylation of eNOS on its key activatory site (Ser 1177) and the 
phosphorylation of Akt (Ser 473) (Figure 7B and 7C) indicating the activation of Akt/eNOS 
that is involved in the positive regulation of NO release. As presented in Figure 7D, HO-1 
expression was successfully induced by CoPP treatment (10 µM) while high glucose (33 
mM) did not affect the protein’s expression.
As depicted in Figure 8A, HUVECs treated intermittently with high glucose for 5 days 
showed significant reduction in tube-like structure formation compared to positive control. 
This effect was reversed by PBA treatment with significant increase in tube-like structure 
formation compared to high glucose alone indicating the involvement of ER stress in this 
process (Figure 8A). Moreover, similar protective effect was noticeable with HO-1 induction 
by CoPP indicating its protective pro-angiogenic role and antagonising the effects of high 
glucose-induced ER stress. This pro-angiogenic effect of HO-1 induction was further 
supported by the observation that CoPP treatment also caused an increase in mRNA (Figure 
8B) and protein (Figure 8C) expression of the key pro-angiogenic factor VEGF-A in 
endothelial cells.
Altogether, these findings provide evidence that the protective role of HO-1 induction by 
CoPP against impaired angiogenesis caused by high glucose in HUVECs is carried out by 
activating the pro-angiogenic VEGF-A—p-eNOS/P-AKT—NO axis and attenuation ER 
stress response.
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4. Discussion
In this study, we provide evidence that HO-1 induction exerts a protective role against ER 
stress-mediated endothelial dysfunction and impaired angiogenic capacity caused by high 
glucose treatment. The effects of HO-1 induction involve several protective mechanisms 
including the alleviation of oxidative stress in addition to inflammatory and apoptotic 
responses induced by ER stress activation. 
High glucose-mediated ER stress response is believed to play a key role in different aspects 
of endothelial dysfunction both in humans and in animal models of diabetes. High glucose
induces ER stress response and ROS production in a close interplay, which ultimately may 
contribute to the pathogenesis of micro- and macro-vascular complications, associated with 
diabetes [31, 32]. Recently, mice injected with streptozotocin to cause diabetes exhibited
enhanced ER stress response in the heart and small mesenteric arteries. Treatment of these 
mice with a chemical chaperone (Tauroursodeoxycholic acid, TUDCA) improved 
endothelium-dependent and -independent relaxation. We report here that exposure of 
HUVECs to high glucose caused an increase in both mRNA and protein expression of key 
ER stress markers (phospho-eIF2-α, BiP, CHOP and ATF-4) indicating that the upstream ER 
stress arm PERK/eIF2-α is activated under these conditions. PERK is the major effector 
controlling the attenuation of protein translation when ER stress ensues through the activation 
of the elongation factor, eIF2-α. Activation of eIF2α allows for selective translation of ATF-4 
that regulates the expression of the pro-apoptotic factor CHOP. We also report that similarly 
to chemical chaperone PBA, the induction of HO-1 by CoPP, reversed the effects of high 
glucose on ER stress indicating an important cross talk between ROS and ER stress in these 
conditions. Consistent with our observations, Kim et al. [33] have reported that that induction 
of HO-1 through the exposure of HUVECs to CO or CoPP prevented thapsigargin-induced 
expression of CHOP [33]. 
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Mannitol, however, caused a moderate increase in the expression phospho-eIF2-α without 
affecting the expression of other ER stress markers. This is possibly because mannitol may 
have enhanced a transient need for more protein synthesis and hence caused a transient 
activation of UPR response.
During ER stress, several mechanisms can lead to increased ROS production including the 
ER itself, which becomes an important source of ROS due to the inhibition of protein 
translation by the PERK/eIF2-α/ATF-4 pathway, in addition to the activation of NADPH 
oxidase complex [34]. As expected, we found here that high glucose-mediated ER stress 
increased ROS production in HUVECs that was blunted by HO-1 induction and PBA 
indicating a strong interplay between ER stress and ROS in high glucose conditions. NADPH 
oxidase is a major source of ROS production in the vasculature [28]. Among other important 
regulatory mechanisms, the phosphorylation of p47phox regulatory subunit was shown to be a 
prerequisite for the activation of NADPH oxidase [29]. We observed here that the 
phosphorylation of p47phox at Ser345 was enhanced in cells exposed intermittently to high 
glucose suggesting the activation of NADPH oxidase complex. The induction of HO-1 by 
CoPP or the alleviation of ER stress response by PBA reduced the phosphorylation of p47phox 
indicating the involvement of ER stress in this process. To the best of our knowledge, this is 
the first time that HO-1 induction or ER stress inhibition was reported to prevent high 
glucose-mediated serine phosphorylation of p47phox in endothelial cells. The phosphorylation 
of p47phox implies a central role for ER stress in the activation of serine/threonine kinase(s) 
that can phosphorylate p47phox. High glucose-mediated ER stress can increase intracellular 
Ca2 + release from the ER, which, in turn, can cause the activation of protein kinase C [35]
which was recently reported to promote the serine phosphorylation of p47phox [36]. However, 
the exact role of this phosphorylation and the activation of NADPH oxidase warrants further 
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investigation to establish a clear mechanistic link between HO-1, ER stress and activation of 
NADPH oxidase. 
Much evidence links ER stress with major inflammatory signalling hubs. For instance, 
PERK/ eIF2-α/ATF-4 arm of ER stress triggers the activation of JNK which is involved in 
the positive regulation of some inflammatory genes and apoptosis [34]. In our hands, high 
glucose-mediated ER stress was associated with the activation of JNK and NF-κB pathways 
and caused a significant increase in the production of IL-6 inflammatory cytokine. All these 
effects were counteracted by HO-1 induction and the inhibition of ER stress indicating the 
involvement of ROS either upstream and/or downstream of ER stress in this process. 
Inflammatory response has been mechanistically linked to oxidative stress [37, 38]. 
Consistent with our findings, previous studies indicated that hyperglycaemia triggers the 
generation of free radicals which activate NF-κB that is known to induce the up-regulation of 
other pro-inflammatory cytokines including IL-6, which can in turn activate ER stress 
response by a vicious cycle and contribute to the maintenance of the inflammatory state 
during ER stress [39].
We observed here that HO-1 induction alleviated the effects of high glucose in activating
several pro-apoptotic pathways, in which ER stress is central, including the activation of JNK 
and PERK/eIF2-α/ATF-4/CHOP pathways. Several mechanisms controlling cell death
following unresolved ER stress have been reported most of which have been prevented by 
HO-1 induction in the present study [40]. In prolonged ER stress, IRE-1α sensor can cause 
the phosphorylation and activation of JNK, which can ultimately induce apoptosis [16]. 
When ER stress becomes severe, the PERK/eIF2α/ATF-4 pathway also activates the 
transcription factor CHOP, which upregulates expression of pro-apoptotic proteins such as 
Bim, and downregulates the expression of anti-apoptotic molecule Bcl-2 [16, 17]. 
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Consistent with other studies, we report here that the activation of JNK and PERK/eIF2-
α/ATF-4/CHOP axis caused by high glucose was associated with a high apoptosis rate in 
HUVECs [41]. HO-1 induction or inhibition of ER stress prevented the activation of these 
pro-apoptotic signals, which was translated into a reduction of apoptosis. These findings
further highlight the important anti-apoptotic role of HO-1. Endogenous HO-1 induction was 
observed in HUVECs exposed to high glucose levels up to 10 mM; however, higher 
concentrations of glucose (>20 mM) did cause a significant downregulation of HO-1 
expression which was linked to an increase in apoptosis rate [41]. Another study by Abraham 
et al. [11] also found that incubation of endothelial cells with high glucose (33 mM) for 7 
days caused a decrease in HO activity and protein expression [11]. This suggests that HO-1 
levels are critical to overcome the pro-apoptotic effects of high glucose. In our study and 
consistent with these previous studies, we found that high glucose (33 mM) did not induce 
HO-1 expression or activity. We observed that these high concentrations of glucose (33 mM) 
failed to increase apoptosis in HUVECs in the presence of HO-1 inducer, CoPP, indicating a 
therapeutic potential for HO-1 induction against high glucose-mediated endothelial apoptosis. 
These pro-survival effects of HO-1 are directly linked to the enzyme’s activity because the 
treatment of HUVECs with SnPP, a potent HO inhibitor, reversed the beneficial effects of 
HO-1 induction on cell survival. 
An important feature of apoptosis is the activation of caspases where the Bcl-2 family plays a 
crucial role in regulating their engagement under ER stress [42]. In our study, we observed 
that HO-1 induction protected HUVECs against high glucose-induced activation of caspases 
3 and 7. Consistent with our results, it was found that under ER stress conditions, through the 
action of JNK-dependent signalling, caspase-3 cleavage and activity is enhanced leading to 
high levels of calcium in the mitochondria [43]. In our study, the activation of caspase-3 
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effector is consistent with the activation by high glucose of PERK/eIF2-α/ATF-4/CHOP 
pathway. 
Perturbations in angiogenesis are tightly linked to endothelial dysfunction and contribute to 
ischemic complications of diabetes. HO-1 was found to possess potent pro-angiogenic 
properties. The overexpression of HO-1 in endothelial cells was reported to enhance cell
proliferation and tube formation capacity [44]. We report here for the first time that HO-1 
induction and inhibition of ER stress in HUVECs prevented the impairment of capillary-like 
structure formation on Matrigel assay caused by intermittent high glucose treatment 
indicating the involvement of ER stress in this process and the therapeutic potential of HO-1 
induction against high glucose-mediated ischemia. In line with our findings, a number of 
studies implicated ER stress in endothelial dysfunction and impaired angiogenic capacity. For 
instance, the chemical chaperone TUDCA was shown to protect against impaired ischemia-
induced neovascularization following hind-limb ischemia after femoral artery ligation in 
db/db diabetic mice [45]. Endothelial dysfunction plays a key role in diabetic microvascular 
dysfunction because endothelial NO is a crucial regulator of angiogenic sprouting [46]. We 
report here that HO-1 induction and ER stress inhibition improved NO production and 
enhanced the activation of Akt/eNOS pathway in HUVECs exposed to high glucose, which
eventually contributes to restoring the capacity of cells to form tube-like structures. The 
concomitant reduction of ROS production in cells treated with CoPP or PBA also contributes 
to the improved NO bioavailability. ER stress can affect NO bioavailability through several 
ways and hence impair angiogenic capacity of endothelial cells. Accumulation of CHOP was 
shown to inhibit eNOS synthesis through a direct interaction with the enzyme’s promoter
while CHOP-deficient mice exhibited an improved postnatal ischemia-induced 
neovascularization [47]. ER stress can also affect endothelial NO bioavailability by causing 
endothelial insulin resistance which may directly and negatively affect endothelial function. 
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Insulin by binding to its receptor, expressed by endothelial cells, can stimulate the release of 
NO by endothelial cells [48], and, thus, endothelial insulin resistance can impair insulin-
mediated NO release [49]. Ozcan et al. reported that the activation of ER stress enhanced NF-
κB and JNK pathways, which then phosphorylated insulin receptor substrate (IRS)-1 on 
serine residues and hence blunted insulin signalling response [13]. In our study, we found 
that high glucose-mediated ER stress was closely associated with the activation of NF-κB and 
JNK pathways, which may in turn contribute to the impairment of endothelial insulin 
response.
Although, the role that heme degradation by-products play in the cyto-protective effects of 
HO-1 in our system was not specifically studied, some evidence in the literature indicate that 
the action of both bilirubin and CO may alleviate ER stress response; however, their exact 
role needs to be further delineated in future studies. Biliverdin and bilirubin are both potent 
antioxidants through a direct ROS scavenging mechanism and were found to prevent 
oxidative stress-mediated cell death [50]. Recently, bilirubin was shown to enhance insulin 
signalling response in a diet-induced obesity mouse model an in db/db diabetic mice through 
the suppression of ER stress response [51]. Bilirubin levels in humans were found to be 
associated with reduced risk for coronary heart disease [50, 52]. CO, the other degradation 
by-product, was found to prevent apoptosis in endothelial cells by activating p38 MAP 
kinase. CO was also shown to improve insulin response by increasing intracellular calcium 
[50]. Recently, it was reported that CO- releasing agent, CORM-2, improved ER stress 
response and blocked the ER stress-mediated impairment in leptin signalling in cells treated 
with ER stress inducers thapsigargin and tunicamycin [53].
Altogether, we demonstrate in the present study the pivotal role of ER stress-mediated cell 
death in high glucose-induced endothelial dysfunction and impaired angiogenic capacity and
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underscore the potential role of HO-1 induction as a key therapeutic modulator for ER stress 
response in ischemic disorders and diabetes.
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Figure Legends:
Figure 1. Validation of conditions of HO-1 induction by CoPP. (A), western blot analysis 
of HO-1 and β-actin expression in HUVECs treated with CoPP (10, 25, 50, 75 and 100 µM) 
for 12 or 24 hours. Representative image from 3 independent experiments. (B), viability 
(MTT) assay of HUVECs treated with CoPP (10, 25, 50, 75 and 100 µM) for 12 or 24 hours. 
Histograms represent pooled normalized data to negative control (CTL) (n=3-6 per group). 
(C), HO-1 activity assay showing bilirubin production (mg/dL) in HUVECs incubated in 
physiological (5 mM) concentration of glucose or in intermittent high glucose (5/33 mM) for 
5 days in the presence or absence of CoPP or SnPP (n=3). Data are presented as mean± SEM 
and were analysed by one-way ANOVA, followed with a Tukey's multiple comparison test. 
*P < 0.05, **P < 0.01, ***P < 0.001 vs. control or indicated groups. CTL, control; HG, high 
glucose.
Figure 2. HO-1 induction in HUVECs attenuates high glucose-induced ER stress. (A, B), 
Relative mRNA expression levels of ER stress target markers BiP (A), CHOP (B) and ATF-4 
(C) normalised against β-actin housekeeping gene (n=6).  (C, D), western blot analysis 
showing protein expression levels of BiP, p-eIF2α (D and E) and ATF-4 (F). Histograms 
represent pooled normalized data to total amount of normalised to β-actin loading control 
expressed as arbitrary units (A.U.) (n=3 per group). Data are presented as mean± SEM and 
were analysed by one-way ANOVA, followed with a Tukey's multiple comparison test. 
*P < 0.05, **P < 0.01, ***P < 0.001 vs. control or indicated groups. CTL, control; HG, high 
glucose; TG, thapsigargin; Man, Mannitol.
Figure 3. HO-1 induction in HUVECs protects against high glucose-induced oxidative 
stress. (A), Measurement of ROS production in HUVECs. Cells were either treated with 
H2O2 (100 µM) for 30 minutes (PC) or incubated with intermittent high glucose (HG) for 5 
days in the presence or absence of PBA, CoPP or Mannitol. In negative control (NC) group, 
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cells where incubated with M200 medium only. Histograms represent the percentage of 
DHE-positive cells to negative control. (B), western blot analysis of protein expression of 
phosphorylated p47phox (Ser345). Histograms represent pooled normalized data to total 
amount of total protein p47phox expressed as arbitrary units (A.U.) (n=4). Data are presented 
as mean± SEM and were analysed by one-way ANOVA, followed with a Tukey's multiple 
comparison test. **P < 0.01, ***P < 0.001 vs.  Control or indicated groups. CTL, control; HG, 
high glucose; PC, positive control; NC, negative control; TG, thapsigargin; Man, Mannitol.
Figure 4. HO-1 induction in HUVECs prevents inflammatory response mediated by 
high glucose-induced ER stress. (A, B), western blot analysis showing protein expression 
levels of p-iKK α/β (A) normalized against iKK and p-c-JUN normalized against β-actin (B). 
Histograms represent pooled normalized data to total amount of respective loading control 
expressed as arbitrary units (A.U.) (n=4 in each group). (C) Relative mRNA expression IL-6 
normalized against β-actin housekeeping gene (n=6). (D) ELISA analysis of IL-6 release in 
culture medium from HUVECs treated with LPS (PC) or high glucose (HG) in the presence 
or absence of CoPP and/or SnPP (n=3). Data are presented as mean± SEM and were analyzed 
by one-way ANOVA, followed with a Tukey's multiple comparison test. *P < 0.05, 
**P < 0.01, ***P < 0.001 vs. control or indicated groups. CTL, control; HG, high glucose; TG, 
thapsigargin; PC, positive control; Man, Mannitol.
Figure 5. HO-1 induction in HUVECs protects against high glucose-induced apoptosis.
(A), Assessment of apoptosis by flow cytometry in HUVECs treated with intermittent high 
glucose (33 mM) using Annexin V and PI staining (n=3). Histograms represent pooled data 
and presented as percentage of control. Data are presented as mean± SEM and were analysed 
by one-way ANOVA, followed with a Tukey's multiple comparison. ***P < 0.001 vs. control 
or indicated groups. CTL, control; NT, negative treatment.
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Figure 6. HO-1 induction in HUVECs protects against high glucose-induced caspases 
3/7 and PAPRP activation. (A), Caspase 3/7 Glo luminescent assay for assessment of 
Caspases 3 and 7 activity (n=3). Cells treated with Staurosporine were used as positive 
control (PC). Untreated cells were used as negative control (NC). (B), western blot analysis 
to determine  presence of cleaved PARP, caspase 3 and caspase 7. Images are representative 
of 4 independetnt experiments. Data are presented as mean± SEM and were analysed by one-
way ANOVA, followed with a Tukey's multiple comparison. ***P < 0.001 vs. control or 
indicated groups. CTL, control; HG, high glucose; PC, positive control; NC, negative control; 
TG, thapsigargin; Man, Mannitol.
Figure 7. HO-1 induction improves NO bioavailability in in HUVECs incubated in high 
glucose. (A), Quantification of nitrite and nitrate productions in HUVECs. Cells were 
incubated in intermittent high glucose (HG) in the presence or absence of CoPP. Supernatants 
were collected and assayed for nitrite and nitrate production (n=4). (B-C), western blot 
analysis of protein expression of p-eNOS (Ser1177) (B), p-Akt (Ser473) (C) and HO-1 (D). 
Histograms represent pooled normalized data to total amount of respective total protein 
expressed as arbitrary units (A.U.) (n=4 in each group). Data are presented as mean± SEM 
and were analysed by one-way ANOVA, followed with a Tukey's multiple comparison test.
*P < 0.05, **P < 0.01, ***P < 0.001 vs. control or indicated groups. CTL, control; HG, high 
glucose.
Figure 8. Alleviation of high glucose-induced ER stress by HO-1 induction improves 
endothelial function and angiogenic capacity in HUVECs. (A), Phase-contrast 
micrographs of HUVECs incubated in complete culture M200 medium (positive control, PC), 
in basal culture medium negative control, NC) or in intermittent high glucose (HG) in the 
presence or absence of CoPP or PBA. Cells were grown on a Matrigel® matrix to favour 
network formation. Images are representative of 3 independent experiments (images taken 
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after 24 h). Capillary length was used to quantify angiogenesis in 5 different blind fields 
(Image J software). Histograms represent pooled data and presented as average length of 
tubes formed in mm. (B), Relative mRNA expression of VEGF-A against GAPDH 
housekeeping gene (n=4). (C), western blot analysis of VEGF-A protein expression. 
Histograms represent pooled normalized data to total amount of β-actin expressed as arbitrary 
units (A.U.) (n=4 in each group). Data are presented as mean± SEM and were analysed by 
one-way ANOVA, followed with a Tukey's multiple comparison test. *P < 0.05, **P < 0.01, 
***P < 0.001 vs.  control or indicated groups. CTL, control; HG, high glucose; PC, positive 
control; NC, negative control.
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